Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 92 articles:
HTML format
Text format



Single Articles


    March 2017
  1. ALTUNDAG K
    Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  2. FUJII T, Ueno NT
    Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    February 2017
  3. PINDER SE, Campbell AF, Bartlett JM, Marshall A, et al
    Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
    Br J Cancer. 2017 Feb 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  4. CATALANO OA, Horn GL, Signore A, Iannace C, et al
    PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  5. PARK YM, O'Brien KM, Zhao S, Weinberg CR, et al
    Gestational diabetes mellitus may be associated with increased risk of breast cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  6. YIP C, Foidart P, Somja J, Truong A, et al
    MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
    Br J Cancer. 2017 Feb 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  7. MORRELL S, Taylor R, Roder D, Robson B, et al
    Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  8. MOYNAHAN ME, Chen D, He W, Sung P, et al
    Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  9. DE PLACIDO S, De Angelis C, Giuliano M, Pizzi C, et al
    Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
    Br J Cancer. 2017 Feb 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  10. HANSEN MF, Jensen SO, Fuchtbauer EM, Martensen PM, et al
    High folic acid diet enhances tumour growth in PyMT-induced breast cancer.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  11. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  12. FUJII T, Kogawa T, Wu J, Sahin AA, et al
    Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  13. KAZARIAN A, Blyuss O, Metodieva G, Gentry-Maharaj A, et al
    Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  14. PARRA K, Valenzuela P, Lerma N, Gallegos A, et al
    Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  15. ROCHEFORT P, Chabaud S, Pierga JY, Tredan O, et al
    Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2016
  16. JOHNS LE, Coleman DA, Swerdlow AJ, Moss SM, et al
    Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  17. UUSITALO E, Kallionpaa RA, Kurki S, Rantanen M, et al
    Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  18. DALDORFF S, Mathiesen RM, Yri OE, Odegard HP, et al
    Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.
    Br J Cancer. 2016 Dec 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  19. SUN J, Chia S
    Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  20. LAMBERTINI M, Pinto AC, Ameye L, Jongen L, et al
    The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
    Br J Cancer. 2016 Nov 1. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  21. MOLLER H, Henson K, Luchtenborg M, Broggio J, et al
    Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England.
    Br J Cancer. 2016 Oct 25. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  22. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  23. LAM SW, Frederiks CN, van der Straaten T, Honkoop AH, et al
    Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  24. OBIORAH I, Sengupta S, Fan P, Jordan VC, et al
    Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  25. COLZANI E, Clements M, Johansson AL, Liljegren A, et al
    Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  26. HOUVENAEGHEL G, Sabatier R, Reyal F, Classe JM, et al
    Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  27. CAMPBELL EJ, Tesson M, Doogan F, Mohammed ZM, et al
    The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  28. TONETTI DA, Chisamore MJ, Grdina W, Schurz H, et al
    Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  29. LIM E, Palmieri C, Tilley WD
    Renewed interest in the progesterone receptor in breast cancer.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  30. PRESTON DL, Kitahara CM, Freedman DM, Sigurdson AJ, et al
    Breast cancer risk and protracted low-to-moderate dose occupational radiation exposure in the US Radiologic Technologists Cohort, 1983-2008.
    Br J Cancer. 2016 Sep 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  31. BOSCO-LEVY P, Jove J, Robinson P, Moore N, et al
    Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.
    Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  32. JONASSON JG, Stefansson OA, Johannsson OT, Sigurdsson H, et al
    Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  33. DE MUNCK L, de Bock GH, Otter R, Reiding D, et al
    Digital vs screen-film mammography in population-based breast cancer screening: performance indicators and tumour characteristics of screen-detected and interval cancers.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  34. SMITH A, Murphy L, Sharp L, O'Connor D, et al
    De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.
    Br J Cancer. 2016 Aug 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  35. JONES ME, Schoemaker MJ, Wright L, McFadden E, et al
    Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
    Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. ZHU B, Mukherjee A, Machiela MJ, Song L, et al
    An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer.
    Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  37. MILLICAN-SLATER RA, Sayers CD, Hanby AM, Hughes TA, et al
    Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  38. PERSSON M, Simonsson M, Markkula A, Rose C, et al
    Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  39. GRAM IT, Little MA, Lund E, Braaten T, et al
    The fraction of breast cancer attributable to smoking: The Norwegian women and cancer study 1991-2012.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  40. SOGAARD M, Farkas DK, Ording AG, Sorensen HT, et al
    Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  41. DREW Y, Ledermann J, Hall G, Rea D, et al
    Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  42. MELVIN JC, Purushotham AD, Garmo H, Pinder SE, et al
    Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  43. WARSCHKOW R, Cerny T, Schmied BM, Guller U, et al
    A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction.
    Br J Cancer. 2016 May 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  44. MESEURE D, Vacher S, Lallemand F, Alsibai KD, et al
    Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
    Br J Cancer. 2016 May 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  45. CIRILLO PM, Benz CC, Cohn BA
    Comment on: 'Hypertensive diseases in pregnancy and breast cancer risk'.
    Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  46. UEDA S, Saeki T, Takeuchi H, Shigekawa T, et al
    In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.
    Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    April 2016
  47. JACKLYN G, Glasziou P, Macaskill P, Barratt A, et al
    Meta-analysis of breast cancer mortality benefit and overdiagnosis adjusted for adherence: improving information on the effects of attending screening mammography.
    Br J Cancer. 2016 Apr 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  48. GANZ PA
    Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress.
    Br J Cancer. 2016;114:953-5.
    PubMed     Text format    


  49. SEO AN, Lee HJ, Kim EJ, Jang MH, et al
    Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
    Br J Cancer. 2016 Apr 26. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  50. SJOBERG E, Augsten M, Bergh J, Jirstrom K, et al
    Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer.
    Br J Cancer. 2016 Apr 26. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  51. AMIR S, Simion C, Umeh-Garcia M, Krig S, et al
    Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer.
    Br J Cancer. 2016 Apr 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  52. TABUNG FK, Steck SE, Liese AD, Zhang J, et al
    Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative.
    Br J Cancer. 2016 Apr 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  53. PHILLIPS KA, Regan MM, Ribi K, Francis PA, et al
    Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
    Br J Cancer. 2016 Apr 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  54. KUERER HM, Yang WT, Krishnamurthy S
    Comment on 'Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'.
    Br J Cancer. 2016 Apr 19. doi: 10.1038/bjc.2015.
    PubMed     Text format    


  55. HEIL J
    Reply to Comment on 'Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'.
    Br J Cancer. 2016 Apr 19. doi: 10.1038/bjc.2015.
    PubMed     Text format    


    March 2016
  56. JANNI W, Harbeck N, Rack B, Augustin D, et al
    Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
    Br J Cancer. 2016 Mar 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  57. MARTINEZ-PEREZ C, Ward C, Turnbull AK, Mullen P, et al
    Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models.
    Br J Cancer. 2016 Mar 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  58. EVANS DG, Donnelly LS, Harkness EF, Astley SM, et al
    Breast cancer risk feedback to women in the UK NHS breast screening population.
    Br J Cancer. 2016 Mar 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  59. BROWN JS, Kaye SB, Yap TA
    PARP inhibitors: the race is on.
    Br J Cancer. 2016;114:713-5.
    PubMed     Text format    


  60. RATNER ES, Zhu YL, Penketh PG, Berenblum J, et al
    Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Br J Cancer. 2016;114:777-86.
    PubMed     Text format     Abstract available


  61. FRY SA, Robertson CE, Swann R, Dwek MV, et al
    Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion.
    Br J Cancer. 2016 Mar 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  62. HEINAVAARA S, Sarkeala T, Anttila A
    Impact of organised mammography screening on breast cancer mortality in a case-control and cohort study.
    Br J Cancer. 2016 Mar 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  63. DREW Y, Ledermann J, Hall G, Rea D, et al
    Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Br J Cancer. 2016 Mar 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  64. PHI XA, Saadatmand S, De Bock GH, Warner E, et al
    Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
    Br J Cancer. 2016;114:631-7.
    PubMed     Text format     Abstract available


  65. GREEN AR, Aleskandarany MA, Agarwal D, Elsheikh S, et al
    MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
    Br J Cancer. 2016 Mar 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  66. KUCHEL A, Robinson T, Comins C, Shere M, et al
    The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
    Br J Cancer. 2016 Mar 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  67. LOUSDAL ML, Kristiansen IS, Moller B, Stovring H, et al
    Effect of organised mammography screening on stage-specific incidence in Norway: population study.
    Br J Cancer. 2016;114:590-6.
    PubMed     Text format     Abstract available


    February 2016
  68. THOMSON AH, McGrane J, Mathew J, Palmer J, et al
    Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.
    Br J Cancer. 2016 Feb 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  69. LOMAKINA ME, Lallemand F, Vacher S, Molinie N, et al
    Arpin downregulation in breast cancer is associated with poor prognosis.
    Br J Cancer. 2016 Feb 11. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    January 2016
  70. DE GLAS NA, Bastiaannet E, Engels CC, de Craen AJ, et al
    Validity of the online PREDICT tool in older patients with breast cancer: a population-based study.
    Br J Cancer. 2016 Jan 19. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  71. MANSI J, Morden J, Bliss JM, Neville M, et al
    Bone marrow micrometastases in early breast cancer-30-year outcome.
    Br J Cancer. 2016 Jan 14. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  72. PAALMAN CH, van Leeuwen FE, Aaronson NK, de Boer AG, et al
    Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study.
    Br J Cancer. 2016;114:81-7.
    PubMed     Text format     Abstract available


  73. ASANO Y, Kashiwagi S, Onoda N, Kurata K, et al
    Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.
    Br J Cancer. 2016;114:14-20.
    PubMed     Text format     Abstract available


  74. RUDOLPH A, Chang-Claude J, Schmidt MK
    Gene-environment interaction and risk of breast cancer.
    Br J Cancer. 2016 Jan 12. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  75. HAMY-PETIT AS, Belin L, Bonsang-Kitzis H, Paquet C, et al
    Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
    Br J Cancer. 2016;114:44-52.
    PubMed     Text format     Abstract available


  76. HILBORN E, Gacic J, Fornander T, Nordenskjold B, et al
    Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer.
    Br J Cancer. 2016 Jan 7. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  77. LEGRIER ME, Bieche I, Gaston J, Beurdeley A, et al
    Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.
    Br J Cancer. 2015 Dec 22. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  78. SUNG H, Garcia-Closas M, Chang-Claude J, Blows FM, et al
    Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
    Br J Cancer. 2015 Dec 17. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  79. ZIELINSKI C, Lang I, Beslija S, Kahan Z, et al
    Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
    Br J Cancer. 2015 Dec 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  80. MELVIN JC, Purushotham AD, Garmo H, Pinder SE, et al
    Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.
    Br J Cancer. 2015 Dec 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  81. MORRIS M, Woods LM, Rogers N, O'Sullivan E, et al
    Ethnicity, deprivation and screening: survival from breast cancer among screening-eligible women in the West Midlands diagnosed from 1989 to 2011.
    Br J Cancer. 2015;113:1640.
    PubMed     Text format    


  82. SOH CL, McNeil K, Owczarek CM, Hardy MP, et al
    Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer.
    Br J Cancer. 2015;113:1640.
    PubMed     Text format    


  83. SCHNEIDER BP, O'Neill A, Shen F, Sledge GW, et al
    Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).
    Br J Cancer. 2015 Dec 1. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    November 2015
  84. HEIL J, Kummel S, Schaefgen B, Paepke S, et al
    Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.
    Br J Cancer. 2015 Nov 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  85. ROMANSKA HM, Potemski P, Krakowska M, Mieszkowska M, et al
    Lack of CD151/integrin alpha3beta1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.
    Br J Cancer. 2015;113:1350-7.
    PubMed     Text format     Abstract available


    October 2015
  86. BERGENFELZ C, Gaber A, Allaoui R, Mehmeti M, et al
    S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
    Br J Cancer. 2015;113:1234-43.
    PubMed     Text format     Abstract available


  87. YOSHIDA M, Ogawa R, Yoshida H, Maeshima A, et al
    TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
    Br J Cancer. 2015;113:1244-8.
    PubMed     Text format     Abstract available


    September 2015
  88. DELPECH Y, Bashour SI, Lousquy R, Rouzier R, et al
    Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma.
    Br J Cancer. 2015;113:1003-9.
    PubMed     Text format     Abstract available


  89. ROSSI L, Laas E, Mallon P, Vincent-Salomon A, et al
    Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.
    Br J Cancer. 2015;113:996-1002.
    PubMed     Text format     Abstract available


  90. AKBAR S, Jordan LB, Purdie CA, Thompson AM, et al
    Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays.
    Br J Cancer. 2015;113:1075-80.
    PubMed     Text format     Abstract available


  91. WEBER RJ, Klompenhouwer EG, Voogd AC, Strobbe LJ, et al
    Comparison of the diagnostic workup of women referred at non-blinded or blinded double reading in a population-based screening mammography programme in the south of the Netherlands.
    Br J Cancer. 2015;113:1094-8.
    PubMed     Text format     Abstract available


  92. BARTLETT JM, Nielsen TO, Gao D, Gelmon KA, et al
    TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
    Br J Cancer. 2015;113:722-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: